GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline (GSK) is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Controlled, Partially Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety and the Occurrence of RSV Associated Respiratory Tract Illness After Administration of a Single Dose of GSK’s RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Older. The study aims to assess the immune response and safety of the RSVPreF3 OA vaccine in adults aged 60 and older, with a focus on comparing results between participants in China and those from other countries.
The intervention being tested is the RSVPreF3 OA investigational vaccine, a biological treatment administered as a single dose. It is designed to prevent respiratory syncytial virus (RSV)-associated respiratory tract illnesses in older adults.
The study employs a randomized, parallel assignment model with a quadruple masking approach, meaning participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary purpose of the study is prevention.
The study began on August 5, 2024, with the last update submitted on August 7, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting the study’s progress and subsequent reporting.
This update could influence GSK’s stock performance positively if the vaccine demonstrates strong efficacy and safety, as it addresses a significant health concern for older adults. The outcome may also affect investor sentiment, especially in comparison to competitors developing similar vaccines.
The study is ongoing, and further details can be found on the ClinicalTrials portal.